StockGlow

NovoCure Limited (038.F)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.

13.00+0.01%Healthcare
Compare 038.F with
StockGlow Score
58
Neutral
BearishBullish
1 year ago+39.5%

The outlook

NovoCure Limited currently reads as neutral based on mixed vs its moving averages, 53% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.

What’s behind the score

Price trendMixed vs its moving averages
52-week range53% of the way from its 52-week low to high
Market cap
$1.51B
52-wk high
17.24
52-wk low
8.12
50-day avg
14.11
200-day avg
11.62
Trailing P/E
—

Similar stocks

3E2.FEtsy, Inc.$71.24-4.50%038.MUNovoCure Ltd$13.54+0.00%3QD.FDatadog, Inc.$235.00-1.05%SRT3.FSartorius Aktiengesellschaft$222.90+0.36%DS3.FDocuSign, Inc.$47.55+1.39%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy